Is Geographic Atrophy taking the center of their universe?

Before you proceed

The link you selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech is not part of the site, nor does it control the content. Genentech does not guarantee the information on the page. Your use of third-party websites is at your own risk and is subject to the third-party website’s privacy policy and terms and conditions for use of such sites.

Chroma and Spectri Clinical Trials for GA

The Chroma and Spectri Phase III clinical trials are designed to evaluate the efficacy and safety of lampalizumab and its ability to reduce the speed of progression of Geographic Atrophy (GA).

What is lampalizumab?

Lampalizumab is an antigen-binding fragment (Fab) of a humanized, monoclonal antibody directed against complement factor D.

Learn more

Support Materials

Patient Resources to help them understand what to expect.

Learn more